Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US12134620B2 · kind B2 · utility
0Cited by
108References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 1, 2019 |
| Grant date | Nov 5, 2024 |
| Priority date | — |
| Expiry date | May 29, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/09
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, L1, L2, L3, A1, A2, A3, A4, G1, G2, E, W, X, Y, Z, m, and n are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.